Sun C, Lim A, De’Ambrosis B, et al. Recurrence Rate of Small Melanoma in Situ on Low-Risk Sites Excised With 5-mm Excisional Margin. JAMA Dermatol (2024).
2024
Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma
Adjuvant nivolumab (Opdivo) in combination with ipilimumab (Yervoy) significantly improved 3-year distant metastasis–free survival (DMFS) rates compared with historical controls in patients with high-risk uveal melanoma, according to findings from the phase 2 HCRN MEL17-309 trial (NCT03528408) presented at the 2024 ASCO Annual Meeting.
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.
New approach to improve targeted skin cancer therapies
(Vienna, 16 July 2024) Targeted therapies are a powerful weapon against skin cancer, but their side effects can severely impact a patient’s quality of life.